PRKAA1 and diabetes mellitus: Metformin, commonly used in diabetes treatment, is also an activator of AMPK, which inhibits gluconeogenesis in the liver, promotes fatty acid oxidation and improves insulin sensitivity, thereby lowering blood glucose levels (Hawley et al., 2002; Liu et al., 2006).